Targeted agents and combinations in ovarian cancer: where are we now?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epithelial ovarian cancer (EOC) is a complex disease with diverse histological subtypes.
• Distinct clinical behaviors are observed across different EOC subtypes.
• Molecular pathway identification is crucial for developing targeted EOC therapies.

Purpose of the Study:

• To review the current landscape of targeted therapies for epithelial ovarian cancer.
• To highlight promising therapeutic strategies for specific EOC subtypes.
• To discuss the potential of novel agents to improve patient outcomes.

Main Methods:

• Literature review of clinical development in ovarian cancer targeted therapy.
• Analysis of successful and emerging therapeutic classes.
• Focus on subtype-specific treatment approaches.

Main Results:

• Anti-angiogenic agents and PARP inhibitors represent the most clinically advanced targeted therapies for EOC.
• Folate receptor antagonists, MEK/BRAF inhibitors (for low-grade serous carcinoma), and immunotherapy show significant promise.
• These agents aim to enhance tumor efficacy and reduce toxicity.

Conclusions:

• Targeted therapies offer a promising future for managing epithelial ovarian cancer.
• Personalized treatment strategies based on molecular subtypes can optimize efficacy.
• Novel agents have the potential to significantly improve outcomes for women with EOC.